|
US4309418A
(en)
|
1980-03-25 |
1982-01-05 |
Sloan-Kettering Research Institute For Cancer |
Anti-tumor agent from human serum and process
|
|
SE8204382L
(sv)
|
1981-07-21 |
1983-01-22 |
Hayashibara Biochem Lab |
Sett att framstella malcellysfaktor och anvendning derav
|
|
US4457916A
(en)
|
1982-08-31 |
1984-07-03 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5288852A
(en)
|
1984-03-06 |
1994-02-22 |
Dainippon Pharmaceutical Co., Ltd. |
Human tumor necrosis factor polypeptides
|
|
US4879226A
(en)
|
1984-04-06 |
1989-11-07 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Novel human physiologically active polypeptide
|
|
DE3423234A1
(de)
|
1984-06-23 |
1986-02-06 |
Boehringer Ingelheim International GmbH, 6507 Ingelheim |
Synergistische mischungen von interferonen und tumor-nekrose-faktor
|
|
US4677064A
(en)
|
1984-11-09 |
1987-06-30 |
Cetus Corporation |
Human tumor necrosis factor
|
|
US4677063A
(en)
|
1985-05-02 |
1987-06-30 |
Cetus Corporation |
Human tumor necrosis factor
|
|
WO1986003751A2
(en)
|
1984-12-21 |
1986-07-03 |
Biogen N.V. |
Purification, production and use of tumor necrosis factors
|
|
US4681760A
(en)
|
1985-04-17 |
1987-07-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of conferring immunotolerance to a specific antigen
|
|
US5059530A
(en)
|
1985-09-30 |
1991-10-22 |
Suntory Ltd. |
Expression vector for human TNF
|
|
US5002876A
(en)
|
1986-09-22 |
1991-03-26 |
Phillips Petroleum Company |
Yeast production of human tumor necrosis factor
|
|
US4985241A
(en)
|
1986-11-21 |
1991-01-15 |
Cetus Corporation |
Therapeutic combination of free-radical scavenger and tumor necrosis factor
|
|
US4963354A
(en)
|
1987-01-21 |
1990-10-16 |
Genentech, Inc. |
Use of tumor necrosis factor (TNF) as an adjuvant
|
|
US5677425A
(en)
*
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5215743A
(en)
|
1988-04-13 |
1993-06-01 |
Maninder Singh |
Tumor necrosis factor formulations
|
|
US5370870A
(en)
|
1989-10-06 |
1994-12-06 |
Genentech, Inc. |
Method for protection against reactive oxygen species
|
|
US5283058A
(en)
|
1990-08-30 |
1994-02-01 |
The General Hospital Corporation |
Methods for inhibiting rejection of transplanted tissue
|
|
US5593698A
(en)
|
1990-10-31 |
1997-01-14 |
Autoimmune, Inc. |
Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
|
|
US5919452A
(en)
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US6984380B1
(en)
|
1991-08-02 |
2006-01-10 |
Denise L. Faustman |
Treatment of diseases involving faulty MHC class I antigen complex presentation
|
|
WO1993002690A1
(en)
|
1991-08-02 |
1993-02-18 |
The General Hospital Corporation |
Diagnosis and treatment of autoimmune diseases
|
|
US5139481A
(en)
|
1991-08-07 |
1992-08-18 |
The General Hospital Corporation |
Treatment for type II diabetes
|
|
US5843425A
(en)
|
1992-02-19 |
1998-12-01 |
The General Hospital Corporation |
Transplantation and graft-versus-host-disease
|
|
ES2168273T3
(es)
|
1992-04-23 |
2002-06-16 |
Sloan Kettering Inst Cancer |
Ligando para el receptor c-kit y metodos de uso del mismo.
|
|
US5939532A
(en)
|
1993-09-07 |
1999-08-17 |
Kyowa Hakko Kogyo Co., Ltd |
Humanized antibodies to ganglioside GM2
|
|
WO1994009137A1
(en)
|
1992-10-15 |
1994-04-28 |
Genentech, Inc. |
Antibodies against type 2 tumor necrosis factor receptor
|
|
US5843452A
(en)
|
1992-11-09 |
1998-12-01 |
Pharmagenesis, Inc. |
Immunotherapy composition and method
|
|
US5560908A
(en)
|
1993-01-22 |
1996-10-01 |
Kanegafuchi Kagaku Kogyo Kabushiki Kaisha |
Therapeutic agent for NIDDM
|
|
US5728385A
(en)
|
1993-08-12 |
1998-03-17 |
Classen Immunotherapies, Inc. |
Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
|
|
US5693617A
(en)
|
1994-03-15 |
1997-12-02 |
Proscript, Inc. |
Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
|
|
US6660268B1
(en)
|
1994-03-18 |
2003-12-09 |
The President And Fellows Of Harvard College |
Proteasome regulation of NF-KB activity
|
|
US5874301A
(en)
|
1994-11-21 |
1999-02-23 |
National Jewish Center For Immunology And Respiratory Medicine |
Embryonic cell populations and methods to isolate such populations
|
|
WO1997008328A1
(en)
|
1995-08-30 |
1997-03-06 |
The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services |
Selective elimination of t cells that recognize specific preselected targets
|
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
|
US5874306A
(en)
|
1996-12-12 |
1999-02-23 |
The Regents Of The University Of California |
Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells
|
|
AU6241698A
(en)
|
1997-01-21 |
1998-08-07 |
Human Genome Sciences, Inc. |
Tace-like and matrilysin-like polypeptides
|
|
WO1999029343A1
(en)
|
1997-12-09 |
1999-06-17 |
Thomas Jefferson University |
Method of treating bladder cancer with wild type vaccinia virus
|
|
US6617171B2
(en)
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
|
US6284879B1
(en)
|
1998-04-16 |
2001-09-04 |
The General Hospital Corporation |
Transport associated protein splice variants
|
|
US6165737A
(en)
|
1998-04-16 |
2000-12-26 |
The University Of Texas System Board Of Regents |
DNA fragmentation factor involved in apoptosis
|
|
EP1077724A2
(en)
|
1998-04-17 |
2001-02-28 |
The University Of Vermont |
Methods and products related to metabolic interactions in disease
|
|
WO1999059632A1
(en)
|
1998-05-18 |
1999-11-25 |
Applied Research Systems Ars Holding N.V. |
Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
|
|
US7485293B1
(en)
|
1999-02-18 |
2009-02-03 |
Faustman Denise L |
Method for inhibiting transplant rejection
|
|
US6599710B1
(en)
|
1999-03-10 |
2003-07-29 |
The General Hospital Corporation |
Treatment of autoimmune disease
|
|
US7015037B1
(en)
|
1999-08-05 |
2006-03-21 |
Regents Of The University Of Minnesota |
Multiponent adult stem cells and methods for isolation
|
|
JP3589912B2
(ja)
|
1999-09-03 |
2004-11-17 |
泰久 福井 |
ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体
|
|
US20010046489A1
(en)
|
1999-12-06 |
2001-11-29 |
Habener Joel E. |
Stem cells of the islets of langerhans and their use in treating diabetes mellitus
|
|
WO2001044472A1
(en)
|
1999-12-16 |
2001-06-21 |
Amgen, Inc. |
Tnfr/opg-like molecules and uses thereof
|
|
US6414218B1
(en)
|
2000-01-18 |
2002-07-02 |
The General Hospital Corporation |
Mouse model for rheumatoid arthritis
|
|
AU2001266604A1
(en)
|
2000-05-26 |
2001-12-11 |
Smith Kline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
US20020160502A1
(en)
|
2000-09-26 |
2002-10-31 |
Roger Williams Hospital |
Recombinant BCG vaccines for the prevention and treatment of cancer
|
|
US20040031066A9
(en)
|
2001-01-18 |
2004-02-12 |
Faustman Denise L. |
Mouse model for rheumatoid arthritis
|
|
US7582313B2
(en)
|
2002-06-27 |
2009-09-01 |
The General Hospital Corporation |
Methods of organ regeneration using Hox 11-expressing pluripotent cells
|
|
US7628988B2
(en)
|
2002-06-27 |
2009-12-08 |
The General Hospital Corporation |
Methods and compositions for treating type 1 diabetes
|
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
|
JP4596916B2
(ja)
|
2002-09-05 |
2010-12-15 |
メディミューン,エルエルシー |
Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
|
|
CN1771055A
(zh)
*
|
2002-09-05 |
2006-05-10 |
免疫医疗公司 |
通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法
|
|
US20040229785A1
(en)
|
2002-11-15 |
2004-11-18 |
Denise Faustman |
Screening methods to identify treatments for autoimmune disease
|
|
US7510877B2
(en)
|
2003-09-26 |
2009-03-31 |
The Regents Of The University Of Michigan |
Hematopoietic stem cell identification and isolation
|
|
JPWO2005035578A1
(ja)
|
2003-10-09 |
2007-11-22 |
協和醗酵工業株式会社 |
ガングリオシドgm2に特異的に結合する抗体組成物
|
|
EP1707627B1
(en)
|
2003-12-25 |
2012-11-14 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic anti-CD40 antibody mutant
|
|
US8563308B2
(en)
|
2004-03-10 |
2013-10-22 |
The Rockefeller University |
Culture-expanded T suppressor cells and methods of use thereof
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
CN101084014A
(zh)
|
2004-10-08 |
2007-12-05 |
杜门蒂斯有限公司 |
抗肿瘤坏死因子受体1的单域抗体及其使用方法
|
|
US20080102054A1
(en)
|
2005-01-18 |
2008-05-01 |
Faustman Denise L |
Compositions Containing Agm Cells And Methods Of Use Thereof
|
|
CA2605253C
(en)
|
2005-04-11 |
2017-06-13 |
Yale University |
Selective modulation of tumour necrosis factor receptors in therapy
|
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
EP2107115A1
(en)
|
2007-01-24 |
2009-10-07 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
|
JP2010531138A
(ja)
|
2007-06-13 |
2010-09-24 |
ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー |
制御性t細胞ならびに同製造および使用方法
|
|
US8900816B2
(en)
|
2007-07-19 |
2014-12-02 |
Duke University |
Assay for anti-EGFRvIII antibodies
|
|
WO2009129538A2
(en)
|
2008-04-18 |
2009-10-22 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
JP5822822B2
(ja)
|
2009-04-17 |
2015-11-24 |
ニューヨーク ユニバーシティ |
Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用
|
|
WO2010124262A1
(en)
|
2009-04-24 |
2010-10-28 |
Allostera Pharma Inc. |
Methods of identification of allosteramers and uses thereof
|
|
KR20120005460A
(ko)
|
2009-04-28 |
2012-01-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
Pkc-세타 억제제를 사용하는 면역학적 장애의 생체외 치료
|
|
US8530392B2
(en)
|
2009-05-13 |
2013-09-10 |
Shionogi & Co., Ltd. |
Test agent for visceral obesity and use thereof
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
WO2011107989A1
(en)
|
2010-03-01 |
2011-09-09 |
Lostam Biopharmaceuticals Ltd |
Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US20130064831A1
(en)
|
2010-05-17 |
2013-03-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
KR101871008B1
(ko)
|
2010-09-16 |
2018-06-25 |
발리오팜 아게 |
항-huTNFR1 항체
|
|
WO2012058137A2
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
|
|
EP2468764A1
(en)
|
2010-12-24 |
2012-06-27 |
Rijksuniversiteit te Groningen |
TNF family ligand variants
|
|
WO2012122464A1
(en)
|
2011-03-10 |
2012-09-13 |
New York University |
Methods and compositions for modulating tnf/tnfr signaling
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
WO2013165982A2
(en)
|
2012-04-30 |
2013-11-07 |
Cell Signaling Technology, Inc. |
Anti-human cytomegalvirus antibodies and use thereof
|
|
US9531457B2
(en)
|
2012-07-18 |
2016-12-27 |
Kyocera Corporation |
Interference management of device-to-device communication in a cellular communication system
|
|
JP6367836B2
(ja)
|
2013-02-07 |
2018-08-01 |
ザ ジェネラル ホスピタル コーポレイション |
T制御性細胞の増殖または枯渇方法
|
|
CN107172880B
(zh)
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
|
EP3180087B1
(en)
|
2014-08-12 |
2019-03-13 |
Alligator Bioscience AB |
Combination therapies with anti cd40 antibodies
|
|
US9172855B1
(en)
|
2014-08-28 |
2015-10-27 |
Avigilon Corporation |
Pendant housing for a camera
|
|
WO2016094309A1
(en)
*
|
2014-12-10 |
2016-06-16 |
Myosotis |
Inhibition of tnf signaling in cancer immunotherapy
|
|
DK3447075T3
(da)
|
2015-05-15 |
2023-11-13 |
Massachusetts Gen Hospital |
Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
|
|
WO2017040312A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
CA3004830A1
(en)
|
2015-11-11 |
2017-05-18 |
Opi Vi- Ip Holdco Llc |
Composition and methods for anti-tnfr2 antibodies
|
|
KR20250007678A
(ko)
*
|
2016-05-13 |
2025-01-14 |
더 제너럴 하스피탈 코포레이션 |
길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
|
|
SG10201912556VA
(en)
*
|
2016-07-20 |
2020-02-27 |
Aerpio Therapeutics Inc |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
IL307684B2
(en)
*
|
2016-09-29 |
2025-04-01 |
Amgen Inc |
Low viscosity antigen binding proteins and methods for preparing them
|
|
JP7054209B2
(ja)
|
2016-11-21 |
2022-04-13 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
エピトープ均質化抗体パネル、ならびにその作製方法および利用
|
|
AU2017384528A1
(en)
*
|
2016-12-19 |
2019-07-04 |
Ichnos Sciences SA |
Novel TNFR agonists and uses thereof
|
|
WO2019094559A2
(en)
|
2017-11-09 |
2019-05-16 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
|
|
WO2020041361A1
(en)
|
2018-08-20 |
2020-02-27 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
|
|
EP3880711A4
(en)
|
2018-11-15 |
2022-12-28 |
The General Hospital Corporation |
Agonistic tumor necrosis factor receptor superfamily polypeptides
|
|
WO2020193718A1
(en)
|
2019-03-27 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
|
WO2021231922A1
(en)
|
2020-05-14 |
2021-11-18 |
The General Hospital Corporation |
Agonistic tumor necrosis factor receptor superfamily polypeptides
|